5-Hydroxytryptamine (5-HT or serotonin) is an important neurotransmitter for a number of brain functions and widely distributed throughout the brain. Physiological and pharmacological relationship between 5-HT1A receptors and serotonin transporter (5-HTT) in the regulation of 5-HT neurotransmission has now been documented. A relationship between 5-HT1A receptors and 5-HTT is also suggested by the pathophysiology of depression and the mechanism of action of antidepressants. We have scanned 42 healthy adults with both [11C] WAY-100635 and [11C] DASB to investigate the anatomical co-distribution of multiple serotonergic markers. We hypothesized that lower 5-HTT densities in the dorsal raphe nucleus (DRN) and limbic regions will be accompanied by lower 5-HT1A receptor density in the same regions, contributing to the 5-HT1A receptor desensitization. In addition, variations in DRN 5-HT1A receptor density can theoretically influence the density and/or function of other serotonin receptor subtypes and the 5-HTT consequent to changes in serotonergic tone. In a comparatively large sample of volunteers, we have shown that the relationship between 5-HT1A and 5-HTT PET indices was complex. We were unable to demonstrate robust, intra-regional relationships between 5-HT1A and 5-HTT densities. Inter-regionally, DRN 5-HT1A receptors were related to cortical (temporal and frontal regions) and paralimbic (insula), but not limbic 5-HTT. This latter finding may reflect differences in 5-HT tone between individuals, and highlights probable substrates sensitive to variations in DRN 5-HT function.
INTRODUCTION
5-Hydroxytryptamine (5-HT or serotonin) neurons are widely distributed throughout the brain, and dysfunction in the serotonergic system is associated with a number of disorders, including depression, anxiety, chronic fatigue syndrome, and schizophrenia (Abi-Dargham, 2007; Cleare et al, 2005; Cowen, 2008; Geyer and Vollenweider, 2008) .
Serotonin cell bodies are clustered in the mesencephalon and densely located in the dorsal raphe nucleus (DRN). 5-HT cell bodies in the DRN send projection fibers throughout the forebrain to limbic, striatal, and cortical regions. Both 5-HT1A and serotonin transporters (5-HTT) are positioned to have a key role in maintaining 5-HT homeostasis due to their location on presynaptic 5-HT neurones (Barnes and Sharp, 1999 ) and on 5-HT projection sites (Kish et al, 2005; Varnäs et al, 2004) . 5-HT1A receptors are present both as somatodendritic autoreceptors on 5-HT cell bodies in the midbrain and brainstem; and as postsynaptic (or heteroreceptors) receptors in 5-HT projection areas. 5-HTT, present on DRN cell bodies, terminal dendrites, and axons, terminate 5-HT neurotransmission by their high-affinity reuptake of released synaptic 5-HT (Hoyer et al, 2002; Barnes and Sharp, 1999) .
It is now accepted that there is a physiological and pharmacological relationship between 5-HT1A receptors and 5-HTT in the regulation of 5-HT neurotransmission (Alexandre et al, 2006; Fox et al, 2010; Gobbi et al, 2001; Li et al, 2000; Mannoury la Cour et al, 2001) . For example, 5-HTT knockout mice have region-specific changes in the adult 5-HT1A receptor density with reductions in dorsal raphe, hypothalamus, and amygdala, but increased or unchanged densities in the hippocampus (Alexandre et al, 2006; Li et al, 2000; Mannoury la Cour et al, 2001) and no changes in entorhinal and frontal cortices. Similarly, mice expressing lower DRN 5-HT1A autoreceptors have increased raphe cell firing rates and larger increases in serotonin levels when administered the selective serotonin reuptake inhibitor (SSRI) fluoxetine, measured in the hippocampus and prefrontal cortex (Richardson-Jones et al, 2010) .
What is not clear from these studies is whether specific associations of 5-HT1A receptor and 5-HTT densities may also be detectable within normal human populations. In addition, variations in DRN 5-HT1A receptor density can theoretically influence the density and/or function of other serotonin receptor subtypes and the serotonin transporter (5-HTT) consequent to changes in serotonergic tone (Richardson-Jones et al, 2010) . Anatomical co-distribution of multiple serotonergic markers can be studied in vivo in the human brain using PET imaging (Frey et al, 2008; Lundberg et al, 2007; Takano et al, 2008) . Indeed, a significant positive linear association between 5-HT1A receptor density indexed using [11C] WAY-100635 and 5-HTT binding indexed using [11C]MADAM has been shown in the brainstem raphe and hippocampus, but not the frontal cortex in a group of 12 volunteers (Lundberg et al, 2007) . In an exploratory analysis, in a group of 17 male volunteers (Takano et al, 2008) showed negative linear associations between [11C] WAY-100635 BP ND and [11C] DASB BP ND (for 5-HTT) in the cingulate, insula, frontal, lateral temporal, and parietal cortices. In an attempt to resolve these inconsistencies, we have scanned 42 healthy adults with both [11C] WAY-100635 and [11C] DASB. We hypothesized that 5-HTT densities in the DRN and limbic regions will be related to 5-HT1A receptor density in the same regions. Given the recent suggestion that these relationships may be nonlinear based on the studies of 5-HT2A and 5-HTT receptor densities , we tested both linear and 2nd and 3rd order polynomial relationships. In addition to our prediction that there will be intra-regional correlations in 5-HTT and 5-HT1A receptor densities in the DRN and limbic areas, we predicted that raphe 5-HT1A receptor density would be related to cortical 5-HTT density due to the variations in 5-HT levels (tone) predicted by 5-HT1A density in the DRN (Richardson-Jones et al, 2010) . All volunteers were also genotyped for the 5-HTTLPR to explore possible modulating influences of genetic variations.
MATERIALS AND METHODS

Participants
Forty-two healthy adult male volunteers (mean age ¼ 38 years; SD ¼ 11 years; range ¼ 25-60 years) were included in this study. None of the participants met Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for current or past psychiatric disorders, and all were physically healthy. In addition, the health status of all volunteers was confirmed by contacting their general practitioners. Family history of depressive disorder was determined by interviewing the participant and the relative's psychiatric history was confirmed from the relative themselves and/or the relative's general practitioner. The role of family history of depression in the co-distribution of serotonergic markers will be reported separately. The study recruited volunteers from two sites in Cambridge and Oxford, UK, and all participants underwent scans at Hammersmith Hospital in London. This study was approved by the local Research Ethics Committees at Cambridge, Oxford and the Hammersmith Hospital, London; and the Administration of Radioactive Substances Advisory Committee, UK. All subjects gave written informed consent.
Data Acquisition
Each subject had two PET scans one each using [11C] WAY-100635and [11C] DASB, and a T1-weighted magnetic resonance scan for brain structural information. The time interval between the PET scans was about 1 week and the order was not fixed. The PET data were acquired on a highsensitivity ECAT EXACT3D (Siemens/CTI, Knoxville, TN, USA) scanner with an axial field of view of 23.4 cm and 95 reconstructed transaxial image planes (Spinks et al, 2000) .
The mean spatial resolution is 4.8±0.2 mm FWHM (transaxial, 1 cm off-axis) and 5.6±0.5 mm (axial, on-axis). A 5 min transmission scan (with a [137]-Cs rotating point source) was performed before each emission scans for scatter and attenuation correction (Watson et al, 1996) .
DASB
[11C] DASB was synthesized as described earlier through the reaction of [11C]methyliodide with the desmethyl precursor (Wilson et al, 2000) . Both the DASB and the precursor desmethyl DASB were supplied by the Target Molecules (Southampton, UK The dynamic PET data were acquired over 90 min in listmode and were then re-binned post-acquisition into a series of 28 frames of increasing lengths.
WAY-100635
[11C] WAY-100635 was synthesized by GE healthcare, MRC-Clinical Sciences Centre by a remotely controlled production process using [11C] carboxylation of an immobilized Gringard reagent as described previously (McCarron et al, 1996) . Dynamic PET data were acquired over 95 min in listmode setting, collecting 23 time frames over 95 min. A bolus injection of [11C] WAY-100635 between 237.12 and 313.33 MBq (mean 300.63 MBq, SD 11.49 MBq) was administered intravenously over 30 s into an antecubital fossa vein. Further details of the scanning protocol used at the Unit have been previously described (Bhagwagar et al, 2007; Hinz et al, 2008) .
Magnetic Resonance Imaging
It was not possible to acquire all the magnetic resonance imaging (MRI) data on the same scanner because of technical problems and de-commissioning of scanners during the study. Consequently the MRI was performed on scanners with a field strength of 0.5 T (0. ). The scans (0.5 T MRIF9 subjects; 1.5 T MRIF17 subjects, and 3 T MRIF16 subjects) were all examined by an independent clinical neuroradiologist for abnormalities. No participants were excluded on the basis of this examination.
Defining Volume of Interest
MRI images were resliced (1 Â 1 Â 1 mm 3 ) and co-registered to the corresponding subject's summed PET image (9-90 min for DASB; 9-95 min for WAY-100635) using a normalized mutual information method, which implements a rigid body (six parameters) transformation using SPM5 (http://www.fil.ion.ucl.ac.uk/spm) to give individual co-registered MRI images. The following regions of interest (ROI) were investigated for both ligands: hippocampus, amygdala, anterior medial temporal lobe, anterior lateral temporal lobe, parahippocampus, superior temporal gyrus, medial inferior temporal gyrus, posterior temporal lobe, insula, anterior cingulate cortex, posterior cingulate cortex, parietal lobe, occipital lobe, orbitofrontal gyrus, precentral gyrus, inferior frontal gyrus, medial frontal gyrus, superior frontal gyrus, and raphe nucleus. In addition the brainstem, caudate nucleus, putamen, thalamus, and globus pallidus were investigated for DASB scans. All regions except raphe were defined on a probabilistic atlas. Raphe was drawn manually by an expert neuroradiologist (Rabiner et al, 2002) and the region used for both ligands was identical for each participant. This atlas has been shown to have high reliability for these regions (Hammers et al, 2002 (Hammers et al, , 2003 and the raphe region was validated using four independents images, assessed by the same blinded rater. The variability (difference/mean) for V T and BP ND (see below for definition of these measurements) was 6.6% and 7.8%, respectively. The SPM MNI T1 template was spatially normalized to the co-registered individual MRI image and the deformation parameters applied to the probabilistic atlas to delineate the ROIs on the individual co-registered MRI. This normalized atlas was resliced to dimensions of the PET images and segmented to obtain the activity from the gray matter only and for the cerebellum ROI delineation the vermis was excluded.
Generation of Plasma Input Function
For accurate quantification of the highly selective radiotracers selected for this study, we used arterial blood sampling as this was recommended for [11C] WAY-100635 (Parsey et al, 2000) and [11C] DASB (Frankle et al, 2006) . For both the ligands, a plasma metabolite-corrected input function was generated and the delay of the arrival of the tracers in the ROIs relative to the brain was determined. The details of the protocols are described in detail elsewhere (Gunn et al, 2000; Hinz et al, 2008; Hinz and Turkheimer, 2006) .
DASB Data Quantification
Graphical analysis of reversible radioligand binding together with the metabolite-corrected plasma input function was used to quantify the [11C] DASB binding in brain tissue relative to the radioligand concentration in arterial plasma. Regional estimates of the total volume of distribution (V T ) were obtained from the slope of the linear part of the plot (Logan, 1990) . Parameters such as the threshold for the graphical analysis t* ¼ 35 min were set as previously optimized for [11C] DASB (Hinz et al, 2008 ).
The following equation was then applied to calculate the binding potential (BP ND ) relative to nondisplaceable uptake:
Cerebellar gray matter was used as a reference region because of comparatively low density of 5-HTT (Kish et al, 2005) . To avoid the spillover from the occipital cortex, the reference region was carefully delineated in cerebellar gray matter with five to eight slices included leaving a margin of several millimeters to the outer borders of the cerebellum (Hirvonen et al, 2006; Parsey et al, 2000) .
WAY Data Quantification
Quantitative tracer kinetic modelling of [11C] WAY-100635 was performed using two-tissue compartmental model with metabolite-corrected plasma input assuming that labelled metabolites did not cross the blood-brain barrier. Details of the model were elaborated by Innis et al (2007) , and Parsey et al (2000) showed that the derivation of BP ND by kinetic analysis using the arterial plasma input function appeared as the method of choice because of its higher testretest reproducibility, lower vulnerability to experimental noise, and absence of bias in comparison with BP ND estimates derived with the simplified reference tissue model.
Genotyping
A total of 40 participants were genotyped for the insertion/ deletion polymorphism located proximal to the transcription initiation site of the 5-HTT-coding region (5-HTTLPR) as described previously (David et al, 2005) . Because of logistic reason we did not manage to genotype the remaining two subjects.
The 5HTTLPR and rs25531 were genotyped according to the protocol by De Luca et al (2005) .
Statistics
Correlational analyses were performed using Pearson's product moment correlation coefficient. In order to minimize false-positive correlations, we first excluded ROIs with a mean BP ND lower than 0.5 and second applied appropriate multiple comparisons correction. This resulted in the inclusion of the following ROIs for DASB BP ND : hippocampus, amygdala, anterior medial temporal lobe, anterior lateral temporal lobe, parahippocampus, superior temporal gyrus, insula, anterior cingulate cortex, posterior cingulate cortex, orbitofrontal gyrus, inferior frontal gyrus, and raphe nucleus. No regions were excluded for WAY-100635 BP ND . On the basis of previous studies and the known organization of the serotonergic system we present three sets of analyses: first, the relationships between WAY-100635 BP ND and DASB BP ND within the raphe nucleus (Lundberg et al, 2007) and the predefined ROIs; second, the relationships between raphe nucleus WAY-100635 BP ND and DASB BP ND across the rest of the brain and finally the relationships between raphe nucleus DASB BP ND and WAY-100635 BP ND across the rest of the brain. To control the family-wise error rate at the a ¼ 0.05, the set of p-values derived from the correlation analyses was corrected using the Hochberg procedure for multiple comparison compounded by the p-plot estimator of the number of true-null hypotheses (Turkheimer et al, 2001) . Age, sex, genotype, and daylight minutes have been included as covariates in the analysis and these factors did not affect the significance of the correlations in this data set. In addition, we used principal component analysis to obtain a summary 'global' measure of BP ND across the predefined anatomical ROIs to conduct linear, and 2nd and 3rd order polynomial regression analyses. All data were analyzed in SPSS for Windows version 17.0 (SPSS).
RESULTS
The mean BP ND for WAY-100635 and DASB across the predefined ROIs is shown in Table 1 .
Correlations between WAY-100635 and DASB BP ND
For the entire sample of volunteers there was a significant relationship between DASB BP ND and WAY-100635 BP ND in the raphe nucleus (r ¼ 0.31, p ¼ 0.045), although this was no longer significant when partialling out the effect of family history of depression. This appears to be due to those with a family history of depression having higher DASB BP ND values when the WAY-100635 BP ND is higher, although this effect only tended toward significance (MANOVA F 2, 39 ¼ 2.77, p ¼ 0.075). For the rest of the brain there were no further statistically significant intra-regional correlations between DASB BP ND and WAY-100635 BP ND (Ps40.34). The global summary measures across all regions (excluding raphe nucleus) for DASB BP ND and WAY-100635 BP ND were also not significantly related using linear, 2nd or 3rd order polynomial curve estimation (Ps40.70).
When we specifically tested the relationship between the raphe WAY-100635 BP ND and DASB BP ND across the brain 6 out of 16 regions showed a significant positive correlation at po0.05. This is illustrated within the correlation matrix shown in Figure 1 . Two regions survived correction for multiple comparisons (Turkheimer et al, 2001) . These values suggest that we cannot distinguish between these models. There were no statistically significant relationships between raphe DASB BP ND and postsynaptic WAY-100635 BP ND (Ps40.10). Participants were classified on the basis of triallelic genotyping of the 5-HTTLPR where L-alleles were classified as either L A or L G . For the purposes of this analysis homozygotes L A L A were coded as L 0 and L G and all S-allele carriers were combined as S 0 . Participants were separated into L 0 (n ¼ 7) and S 0 -carriers (n ¼ 33; Nakamura et al, 2000; Hu et al, 2005; Zalsman et al, 2006) . Similar to the whole group analysis there were no statistically significant intraregional correlations between DASB BP ND and WAY-100635 BP ND in either of the genotypic groups. When we specifically tested the relationship between the raphe WAY-100635 BP ND and DASB BP ND , 6 out of 17 regions in the LL group showed a significant positive correlation at po0.05, overlapping with the regions from the total sample, but also including the anterior temporal lobes, parahippocampal gyrus, and putamen. None of these correlations survived multiple comparisons correction using the Hochberg procedure (Turkheimer et al, 2001) , although the sample size may have limited our ability to detect significant changes.
The Effects of Age and 5-HTTLPR Allelic Variations on WAY-100635 and DASB BP
Age was inversely associated with WAY-100635 BP ND in 9 out of 18 brain regions (po0.05) although none of these correlations survived multiple comparisons correction. Age was positively associated with DASB BP ND in 2 out of 17 regions, and again none of these correlations survived multiple comparisons correction. MANOVA was used to compare WAY-100635 BP and DASB BP between the 5-HTTLPR groups (with age as a covariate) for all regions. For WAY-100635 BP ND there were no differences between 5-HTTLPR groups (F 19, 17 ¼ 0.59, p ¼ 0.87). For DASB BP ND was higher in the S 0 -carriers than the L 0 group (F 24, 12 ¼ 3.09, p ¼ 0.023), although the small number of participants in the L 0 group (n ¼ 7) compared with the S 0 -carriers makes it difficult to draw clear conclusions from this difference.
DISCUSSION
The main findings of the present study are that, in the largest sample reported to date, DRN WAY-100635 BP ND , a putative index of serotonergic tone, was positively correlated with DASB BP ND in insula, superior temporal gyrus, but not limbic regions (eg, amygdala and hippocampus); this relationship was not modulated by 5-HTTLPR variations.
We did not find support for our first hypothesis that lower 5-HTT densities in limbic regions will be accompanied by lower 5-HT1A receptor density in the same regions. This finding in a group of 42 volunteers clarifies the inconsistent results reported to date (Frey et al, 2008; Lundberg et al, 2007; Takano et al, 2008) , which used smaller sample sizes of 8-14 volunteers. Thus, our results indicate that within limbic and cortical brain regions in vivo PET measurements of WAY-100635 BP ND and DASB BP ND appear to act as independent markers of serotonergic function. Within the raphe nucleus these two presynaptic serotonergic markers were weakly related. This was not unexpected because both of these receptor subtypes in the DRN will be present in proportion with the number of 5-HT neurons. Intriguingly, controlling family history of depression reduced this correlation, because of the relatively higher conjoint BP ND values for the two tracers, although this effect only tended toward significance. Whether the same effect is present in patients diagnosed with depression is not known. Our data provide evidence that variations in DRN 5-HT1A receptor density can influence the density and/or function of other serotonin receptor subtypes. However, the precise causal pathway and etiology of this relationship cannot be determined from this data alone. On the one hand, reduced DRN 5-HT neuron firing (and presumably serotonergic tone) due to higher DRN 5-HT1A density might be predicted to be compensated for by reduced 5-HTT density at projection sites; this opposes our findings. Alternatively, we can speculate that 5-HT release, known to be dependent on burst firing of sub-populations of DRN 5-HT neurons (Gartside et al, 2000) , determines 5-HTT density. The relationship between burst firing and 5-HT1A density is not currently known.
The relationship between DRN 5-HT1A density and insula, superior temporal and inferior frontal cortical 5-HTT may reflect serotonergic control of their known associations with specific aspects of emotional and executive processing. The insula cortex, which forms part of a so-called 'paralimbic' circuit is known to be important for the representation and monitoring of emotional states (Critchley et al, 2004) , the superior temporal gyrus has been associated with the processing of both facial and other social stimuli (Habel et al, 2005; Ashwin et al, 2007; Barraclough et al, 2005) and the inferior frontal gyrus is important in impulsive behavior, which may be impaired in patients with depression. Indeed functionality within these regions is sensitive to serotonergic manipulations with SSRI administration (Smith et al, 2002; Anderson et al, 2007; Arce et al, 2008; Nemoto et al, 2003) , and tryptophan depletion (Fusar-poli et al, 2007; Rubia et al, 2005) . Although it is known that sub-populations of 5-HT neurons are present in the midbrain, their differential anatomical connectivity is not known. The regional differences in correlation may thus be due to 5-HT anatomical connectivity, for example, DRN axons contribute more to the serotonergic cortical innervations compared with the other midbrain nuclei (Hornung, 2003) . However, our findings do not necessarily imply that 5-HT1A binding in the raphe nucleus cannot also influence limbic function. For example, Fisher et al (2006) , combining PET and functional MRI measurements, showed 5-HT1A BP ND in the DRN predicts amygdala activation to facial expressions of emotion.
Our findings may have relevance for understanding antidepressant action, although in the absence of supporting multi-ligand data following SSRI administration this must be considered as preliminary. It is generally accepted that the acute administration of SSRI increases synaptic 5-HT, which in turn activates 5-HT1A autoreceptors and reduces DRN firing (Hjorth et al, 2000) . Recently, Richardson-Jones et al (2010) selectively knocked out raphe 5-HT1A autoreceptors without altering 5-HT1A heteroreceptors in mice. They showed that mice expressing higher 5-HT1A autoreceptor levels when compared with lower 5-HT1A expressing mice had a reduced 5-HT response to acute administration of the antidepressant fluoxetine. They conclude that intrinsic autoreceptor levels and serotonergic tone before the onset of treatment are a critical aspect of antidepressant action. In addition, mice overexpressing 5-HTT in contrast to 5-HTT knockout mice have reduced extracellular 5-HT levels in many brain regions including cortex (Jennings et al, 2006) . When taken together, these findings indicate that combined knowledge of 5-HTT and 5-HT1A autoreceptor density may have predictive value in understanding antidepressant response. Based on our preliminary findings in healthy volunteers, we speculate that patients with high 5-HTT density in the insula, superior temporal gyrus, and inferior frontal gyrus, when combined with high DRN 5-HT1A receptor density would be predicted to have a delayed response to SSRIs. This will need to be evaluated in future studies in patients with depressive disorders.
The potential role for genetic variations in, for example, transporter efficiency is poorly addressed in our sample because of the expected low number of those with L 0 genotype (n ¼ 7) compared with the S 0 -carriers (n ¼ 33). It is nonetheless intriguing to note that the strength of correlation observed, despite not reaching statistical significance, was greater in the smaller, L 0 group, which may align with the suggestion that this group have a more stable regulation of serotonin transmission .
These results contrast with the recently proposed inverted U-shaped relationship between 5-HT2A receptor density measured using [11C]altanserin and 5-HTT measured with [11C] DASB in a group of 46 volunteers (22 female; Erritzoe et al, 2010) . The authors also predicted an inverted U-shaped relationship between 5-HT1A receptor density and 5-HTT in the hippocampus and frontal lobes. We were unable to support this prediction. However, unlike Erritzoe et al (2010) , we included only male volunteers and it is possible that there may be gender differences in the 5-HTT and 5-HT1A correlations observed.
CONCLUSIONS
In a comparatively large sample of volunteers, we have shown that the relationship between 5-HT1A and 5-HTT PET indices was complex. We were unable to demonstrate robust, intra-regional relationships between 5-HT1A and 5-HTT densities. Inter-regionally, DRN 5-HT1A receptors were related to cortical (temporal and frontal regions) and paralimbic (insula), but not limbic 5-HTT. This latter finding may reflect differences in 5-HT tone between individuals, and highlights probable substrates sensitive to variations in DRN 5-HT function. DISCLOSURE SB, FT, RH, MM, OH, and SS declare no conflict of interest, PG has served as an occasional consultant to GlaxoSmithKline, Merck, and Pfizer, ER is a full-time employee and holds shares in GSK. VM was a full-time employee of GSK and is currently a full-time employee of Takeda Global Research and Development Centre (Europe). VM continues to hold shares in GSK.
